Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Novel Adenoviral Vector Targets Tumor Blood Vessel Endothelial Cells

By BiotechDaily International staff writers
Posted on 07 Jan 2014
Image: A case where a primary kidney tumor spread to an ovary: The vectors gathering in the metastatic tumor vessels glow green. The red staining shows the normal blood vessels of the ovary (Photo courtesy of Dr. David T. Curiel and Dr. Jeffrey M. Arbeit, Washington University School of Medicine).
Image: A case where a primary kidney tumor spread to an ovary: The vectors gathering in the metastatic tumor vessels glow green. The red staining shows the normal blood vessels of the ovary (Photo courtesy of Dr. David T. Curiel and Dr. Jeffrey M. Arbeit, Washington University School of Medicine).
Researchers working with mouse cancer models used a novel gene-therapy approach to demonstrate the potential for directing therapeutic agents specifically to tumor blood vessels while avoid interaction with the liver or other normal tissues.

Investigators at the Washington University School of Medicine (St. Louis, MO, USA) used a first-generation, inactivated adenoviral (Ad5) vector to transport three kb (kilobases) of the human roundabout4 (ROBO4) enhancer/promoter gene transcriptionally complexed to an enhanced green fluorescent protein (EGFP) reporter.

Robo4 is an endothelial cell-specific member of the Roundabout axon guidance receptor family that specifically binds to UNC5B, a vascular Netrin receptor. Robo4 maintains blood vessel integrity by activating UNC5B, which inhibits signaling downstream of vascular endothelial growth factor (VEGF).

In the current study, which was published in the December 23, 2013, online edition of the journal PLOS ONE, the investigators intravenously injected the Ad/ROBO4/green fluorescent vector into immunodeficient mice bearing 786-O renal cell carcinoma subcutaneous (SC) xenografts and kidney orthotopic (KO) tumors.

Results revealed that Ad5ROBO4 directed enhanced green fluorescent protein expression to the tumor neovasculature, whereas a vector whose reporter was controlled by the human Cytomegalovirus (CMV) enhancer/promoter produced sporadic endothelial cell reporter expression in only one or two vessels throughout the tumors.

“We do not want to kill tumor vessels,” said senior author Dr. Jeffrey M. Arbeit, professor of urologic surgery, cell biology, and physiology at the Washington University School of Medicine. “We want to hijack them and turn them into factories for producing molecules that alter the tumor microenvironment so that it no longer nurtures the tumor. This could stop the tumor growth itself or cooperate with standard chemotherapy and radiation to make them more effective. One advantage of this strategy is that it could be applied to nearly all of the most common cancers affecting patients.”

Related Links:

Washington University School of Medicine



comments powered by Disqus

Channels

Drug Discovery

view channel

Ibuprofen May Restore Immune Function in Older Individuals

New research suggests that macrophages from the lungs of old mice respond differently to infections than those of young mice, and ibuprofen given to the mice reversed these changes. New research using lab mice suggests that the solution to more youthful immune function might already be a common over-the-counter pain reliever.... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Lab Technologies

view channel
Image: Leica Microsystems launches the inverted research microscope platform Leica DMi8 (Photo courtesy of Leica Microsystems).

New Inverted Microscope Designed to Readily Adapt to Changing Research Demands

A new inverted microscope for biotech and other life science laboratories was designed to readily accommodate modifications and upgrades to allow it to keep current with changing research demands and interests.... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.